WCY-8-67 (TFA)

WCY-8-67 TFA is an orally active and selective USP5 inhibitor, with an IC50 value of 1.33 μM. WCY-8-67 TFA induces apoptosis and suppresses JAK/STAT3 and PI3K/AKT signaling pathways. WCY-8-67 TFA inhibits proliferation of AE-positive AML cells, induces G1 phase arrest and differentiation of AML cells. WCY-8-67 TFA demonstrates potent anti-leukemic efficacy in mice. WCY-8-67 TFA can be used for the study of acute myeloid leukemia[1].

Product Specifications

UNSPSC

12352005

Target

Akt; Apoptosis; Deubiquitinase; JAK; PI3K; STAT

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Field of Research

Cancer

Purity

99.40

Smiles

OC(C(F)(F)F)=O.CN(C)CCN(C1=C2C(CN(C3=C4C=CC=CC4=C(F)C=C3)C2)=NC(N5CCNCC5)=N1)C.OC(C(F)(F)F)=O.OC(C(F)(F)F)=O.OC(C(F)(F)F)=O

Molecular Formula

C33H36F13N7O8

Molecular Weight

905.66

References & Citations

[1]Ma L, et al. USP5 inhibition enables potential therapy for t (8;21) AML through ubiquitin-mediated AML1-ETO degradation in patient-derived xenografts. Sci Transl Med. 2025 Sep 24;17 (817) :eadt9100.